cytosine has been researched along with Leukemia, Myeloid in 15 studies
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia." | 9.10 | Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. ( Andreeff, M; Baker, SD; Bivins, C; Cortes, JE; Garcia-Manero, G; Giles, FJ; Jolivet, J; Kantarjian, HM; Miller, CB; O'Brien, SM; Thomas, DA, 2002) |
| "To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia." | 9.09 | Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. ( Baker, SD; Beran, M; Bivins, C; Cortes, JE; Giles, FJ; Jolivet, J; Kantarjian, HM; O'Brien, S; Smith, TL; Thomas, DA, 2001) |
| "Over an eight-month period from October 1997 to May 1998, four patients who had received bone marrow transplant (BMT) from unrelated donor presented with severe mucosal cutaneous infections involving acyclovir resistant herpes simplex virus 1 (HSV-1)." | 7.71 | Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation. ( Bordigoni, P; Carret, AS; Corsaro, D; Dauendorffer, JN; Edert, D; Le Faou, A; Venard, V, 2001) |
| "Patients with refractory acute myeloid leukemia (AML), advanced myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP) were initially randomly assigned to receive troxacitabine 5." | 5.10 | Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. ( Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA, 2003) |
| "To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia." | 5.10 | Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. ( Andreeff, M; Baker, SD; Bivins, C; Cortes, JE; Garcia-Manero, G; Giles, FJ; Jolivet, J; Kantarjian, HM; Miller, CB; O'Brien, SM; Thomas, DA, 2002) |
| "To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia." | 5.09 | Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. ( Baker, SD; Beran, M; Bivins, C; Cortes, JE; Giles, FJ; Jolivet, J; Kantarjian, HM; O'Brien, S; Smith, TL; Thomas, DA, 2001) |
| "Nucleoside analogues (NA) are essential components of AML induction therapy (cytosine arabinoside), effective treatments of lymphoproliferative disorders (fludarabine, cladribine) and are also used in the treatment of some solid tumors (gemcitabine)." | 4.81 | Nucleoside analogues: mechanisms of drug resistance and reversal strategies. ( Dumontet, C; Galmarini, CM; Mackey, JR, 2001) |
| "Over an eight-month period from October 1997 to May 1998, four patients who had received bone marrow transplant (BMT) from unrelated donor presented with severe mucosal cutaneous infections involving acyclovir resistant herpes simplex virus 1 (HSV-1)." | 3.71 | Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation. ( Bordigoni, P; Carret, AS; Corsaro, D; Dauendorffer, JN; Edert, D; Le Faou, A; Venard, V, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (66.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kroeze, LI | 1 |
| Aslanyan, MG | 1 |
| van Rooij, A | 1 |
| Koorenhof-Scheele, TN | 1 |
| Massop, M | 1 |
| Carell, T | 1 |
| Boezeman, JB | 1 |
| Marie, JP | 1 |
| Halkes, CJ | 1 |
| de Witte, T | 1 |
| Huls, G | 1 |
| Suciu, S | 1 |
| Wevers, RA | 1 |
| van der Reijden, BA | 1 |
| Jansen, JH | 1 |
| Meldi, KM | 1 |
| Figueroa, ME | 1 |
| Han, JA | 1 |
| An, J | 1 |
| Ko, M | 1 |
| Stresemann, C | 1 |
| Bokelmann, I | 1 |
| Mahlknecht, U | 1 |
| Lyko, F | 1 |
| Giles, FJ | 6 |
| Alvarado, Y | 1 |
| Kantarjian, HM | 5 |
| Cortes, JE | 5 |
| Apostolidou, E | 1 |
| Bivins, C | 3 |
| Giles, F | 1 |
| Garcia-Manero, G | 4 |
| O'Brien, S | 3 |
| Estey, E | 1 |
| Kantarjian, H | 1 |
| Faderl, S | 2 |
| Thomas, DA | 4 |
| Douer, D | 1 |
| Levine, AM | 1 |
| Koller, CA | 1 |
| Jeha, SS | 1 |
| O'Brien, SM | 2 |
| Estey, EH | 2 |
| Verstovsek, S | 1 |
| Ferrajoli, A | 1 |
| Wathen, JK | 1 |
| Xiao, LC | 1 |
| Berry, DA | 1 |
| Walker, BK | 1 |
| Raich, PC | 1 |
| Baker, SD | 2 |
| Smith, TL | 1 |
| Beran, M | 1 |
| Jolivet, J | 2 |
| Galmarini, CM | 1 |
| Mackey, JR | 1 |
| Dumontet, C | 1 |
| Venard, V | 1 |
| Dauendorffer, JN | 1 |
| Carret, AS | 1 |
| Corsaro, D | 1 |
| Edert, D | 1 |
| Bordigoni, P | 1 |
| Le Faou, A | 1 |
| Miller, CB | 1 |
| Andreeff, M | 1 |
| Lyon, SB | 1 |
| Buonocore, L | 1 |
| Miller, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and t[NCT00004128] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for cytosine and Leukemia, Myeloid
| Article | Year |
|---|---|
Cytosine modifications in myeloid malignancies.
Topics: Animals; Cytosine; DNA Methylation; Epigenomics; Hematologic Neoplasms; Humans; Leukemia, Myeloid; M | 2015 |
Functions of TET Proteins in Hematopoietic Transformation.
Topics: 5-Methylcytosine; Animals; Cell Transformation, Neoplastic; Cytosine; Dioxygenases; DNA (Cytosine-5- | 2015 |
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Mon | 2002 |
Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Topics: 2-Chloroadenosine; 5'-Nucleotidase; Acute Disease; Animals; Antimetabolites, Antineoplastic; Arabino | 2001 |
8 trials available for cytosine and Leukemia, Myeloid
| Article | Year |
|---|---|
Characterization of acute myeloid leukemia based on levels of global hydroxymethylation.
Topics: 5-Methylcytosine; Acute Disease; Adolescent; Adult; Aged; Cytosine; Dioxygenases; DNA (Cytosine-5-)- | 2014 |
Azacytidine causes complex DNA methylation responses in myeloid leukemia.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cytosine; Decitabine; DNA Methylation; Genome, | 2008 |
Troxacitabine activity in extramedullary myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytosine; Dioxolanes; Fem | 2002 |
Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Mon | 2002 |
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2003 |
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2003 |
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Blast Crisis; Cytosine; Dioxolanes; Dose-Response | 2001 |
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Female; Humans; Leukemi | 2002 |
3 other studies available for cytosine and Leukemia, Myeloid
| Article | Year |
|---|---|
The treatment of acute leukemia in adults.
Topics: Adult; Agranulocytosis; Blood Transfusion; Bone Marrow Transplantation; Cytosine; Doxorubicin; Hemor | 1980 |
Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Acyclovir; Adolescent; Amino Acid Substitution; Antiviral Agents; Bone Marrow Transpl | 2001 |
Naturally occurring methylation inhibitor: DNA hypomethylation and hemoglobin synthesis in human K562 cells.
Topics: 5-Methylcytosine; Cell Division; Cell Line; Cell Nucleus; Cytosine; DNA (Cytosine-5-)-Methyltransfer | 1987 |